Age at onset (years) . | Incremental cost-effectiveness ratio . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | Complication utilities . | . | . | . | . | . | |||||
. | Original . | Patient . | Original . | Patient . | Original . | Patient . | |||||
. | Treatment utilities . | . | . | . | . | . | |||||
. | Original . | Original . | Patient, insulin . | Patient, insulin . | Patient, orals . | Patient, orals . | |||||
60–65 | 136 | 78 (75–81) | Dom. | Dom. | 90 (38–537) | 67 (39–209) | |||||
65–70 | 328 | 168 (161–176) | Dom. | Dom. | 127 (Dom. −987) | 101 (39–670) | |||||
70–75 | 746 | 354 (339–371) | Dom. | Dom. | 149 (Dom. −1,470) | 127 (Dom. −834) | |||||
75–80 | 2,284 | 953 (907–1,006) | Dom. | Dom. | 165 (Dom. −1,200) | 152 (Dom. −1,294) | |||||
80–85 | 7,544 | 2,852 (2,709–3,019) | Dom. | Dom. | 159 (Dom. −1,602) | 152 (Dom. −1,281) | |||||
85–90 | 24,205 | 8,912 (8,446–9,449) | Dom. | Dom. | 142 (Dom. −1,190) | 134 (Dom. −931) |
Age at onset (years) . | Incremental cost-effectiveness ratio . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | Complication utilities . | . | . | . | . | . | |||||
. | Original . | Patient . | Original . | Patient . | Original . | Patient . | |||||
. | Treatment utilities . | . | . | . | . | . | |||||
. | Original . | Original . | Patient, insulin . | Patient, insulin . | Patient, orals . | Patient, orals . | |||||
60–65 | 136 | 78 (75–81) | Dom. | Dom. | 90 (38–537) | 67 (39–209) | |||||
65–70 | 328 | 168 (161–176) | Dom. | Dom. | 127 (Dom. −987) | 101 (39–670) | |||||
70–75 | 746 | 354 (339–371) | Dom. | Dom. | 149 (Dom. −1,470) | 127 (Dom. −834) | |||||
75–80 | 2,284 | 953 (907–1,006) | Dom. | Dom. | 165 (Dom. −1,200) | 152 (Dom. −1,294) | |||||
80–85 | 7,544 | 2,852 (2,709–3,019) | Dom. | Dom. | 159 (Dom. −1,602) | 152 (Dom. −1,281) | |||||
85–90 | 24,205 | 8,912 (8,446–9,449) | Dom. | Dom. | 142 (Dom. −1,190) | 134 (Dom. −931) |
Data are means (95% CI) in thousands of dollars/QALY, unless otherwise indicated.
Columns 2–7 illustrate the impact of distinct combinations of original and patient utilities on the relative cost-effectiveness of intensive glucose control versus conventional glucose control for hypothetical patients 65–90 years of age at disease onset. Dom., dominated (the alternative therapy is both harmful and more expensive); insulin, utility for intensive glucose control with insulin used; orals, utility for intensive glucose control with oral medications used.